Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, Global Outlook and Forecast 2022-2028
Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.
This report contains market size and forecasts of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics in Global, including the following market information:
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market was valued at 3606.5 million in 2021 and is projected to reach US$ 4721.5 million by 2028, at a CAGR of 3.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Therapeutics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics include AbbVie, Allergan, Nordmark Arzneimittel, Digestive Care, Janssen Pharmaceuticals, Cilian, Anthera Pharmaceuticals and AzurRx Biopharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, by Type, 2021 (%)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, by Application, 2021 (%)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics in Global, including the following market information:
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market was valued at 3606.5 million in 2021 and is projected to reach US$ 4721.5 million by 2028, at a CAGR of 3.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Therapeutics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics include AbbVie, Allergan, Nordmark Arzneimittel, Digestive Care, Janssen Pharmaceuticals, Cilian, Anthera Pharmaceuticals and AzurRx Biopharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, by Type, 2021 (%)
- Therapeutics
- Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AbbVie
- Allergan
- Nordmark Arzneimittel
- Digestive Care
- Janssen Pharmaceuticals
- Cilian
- Anthera Pharmaceuticals
- AzurRx Biopharma
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS OVERALL MARKET SIZE
2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size: 2021 VS 2028
2.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players in Global Market
3.2 Top Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies Ranked by Revenue
3.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Markets, 2021 & 2028
4.1.2 Therapeutics
4.1.3 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
4.2 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2022
4.2.2 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2023-2028
4.2.3 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Specialty Clinics
5.2 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2022
5.2.2 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2023-2028
5.2.3 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2022
6.2.2 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2023-2028
6.2.3 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.3.2 US Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.3.3 Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.3.4 Mexico Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.4.2 Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.3 France Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.4 U.K. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.5 Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.6 Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.7 Nordic Countries Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.8 Benelux Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.5.2 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.3 Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.4 South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.5 Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.6 India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.6.2 Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.6.3 Argentina Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.7.2 Turkey Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7.3 Israel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7.4 Saudi Arabia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7.5 UAE Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 AbbVie
7.1.1 AbbVie Corporate Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.1.4 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.1.5 AbbVie Key News
7.2 Allergan
7.2.1 Allergan Corporate Summary
7.2.2 Allergan Business Overview
7.2.3 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.2.4 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.2.5 Allergan Key News
7.3 Nordmark Arzneimittel
7.3.1 Nordmark Arzneimittel Corporate Summary
7.3.2 Nordmark Arzneimittel Business Overview
7.3.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.3.4 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.3.5 Nordmark Arzneimittel Key News
7.4 Digestive Care
7.4.1 Digestive Care Corporate Summary
7.4.2 Digestive Care Business Overview
7.4.3 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.4.4 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.4.5 Digestive Care Key News
7.5 Janssen Pharmaceuticals
7.5.1 Janssen Pharmaceuticals Corporate Summary
7.5.2 Janssen Pharmaceuticals Business Overview
7.5.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.5.4 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.5.5 Janssen Pharmaceuticals Key News
7.6 Cilian
7.6.1 Cilian Corporate Summary
7.6.2 Cilian Business Overview
7.6.3 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.6.4 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.6.5 Cilian Key News
7.7 Anthera Pharmaceuticals
7.7.1 Anthera Pharmaceuticals Corporate Summary
7.7.2 Anthera Pharmaceuticals Business Overview
7.7.3 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.7.4 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.7.5 Anthera Pharmaceuticals Key News
7.8 AzurRx Biopharma
7.8.1 AzurRx Biopharma Corporate Summary
7.8.2 AzurRx Biopharma Business Overview
7.8.3 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.8.4 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.8.5 AzurRx Biopharma Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS OVERALL MARKET SIZE
2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size: 2021 VS 2028
2.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players in Global Market
3.2 Top Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies Ranked by Revenue
3.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Markets, 2021 & 2028
4.1.2 Therapeutics
4.1.3 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
4.2 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2022
4.2.2 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2023-2028
4.2.3 By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Specialty Clinics
5.2 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2022
5.2.2 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2023-2028
5.2.3 By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2022
6.2.2 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2023-2028
6.2.3 By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.3.2 US Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.3.3 Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.3.4 Mexico Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.4.2 Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.3 France Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.4 U.K. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.5 Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.6 Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.7 Nordic Countries Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.4.8 Benelux Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.5.2 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.3 Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.4 South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.5 Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.5.6 India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.6.2 Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.6.3 Argentina Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028
6.7.2 Turkey Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7.3 Israel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7.4 Saudi Arabia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
6.7.5 UAE Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 AbbVie
7.1.1 AbbVie Corporate Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.1.4 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.1.5 AbbVie Key News
7.2 Allergan
7.2.1 Allergan Corporate Summary
7.2.2 Allergan Business Overview
7.2.3 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.2.4 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.2.5 Allergan Key News
7.3 Nordmark Arzneimittel
7.3.1 Nordmark Arzneimittel Corporate Summary
7.3.2 Nordmark Arzneimittel Business Overview
7.3.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.3.4 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.3.5 Nordmark Arzneimittel Key News
7.4 Digestive Care
7.4.1 Digestive Care Corporate Summary
7.4.2 Digestive Care Business Overview
7.4.3 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.4.4 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.4.5 Digestive Care Key News
7.5 Janssen Pharmaceuticals
7.5.1 Janssen Pharmaceuticals Corporate Summary
7.5.2 Janssen Pharmaceuticals Business Overview
7.5.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.5.4 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.5.5 Janssen Pharmaceuticals Key News
7.6 Cilian
7.6.1 Cilian Corporate Summary
7.6.2 Cilian Business Overview
7.6.3 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.6.4 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.6.5 Cilian Key News
7.7 Anthera Pharmaceuticals
7.7.1 Anthera Pharmaceuticals Corporate Summary
7.7.2 Anthera Pharmaceuticals Business Overview
7.7.3 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.7.4 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.7.5 Anthera Pharmaceuticals Key News
7.8 AzurRx Biopharma
7.8.1 AzurRx Biopharma Corporate Summary
7.8.2 AzurRx Biopharma Business Overview
7.8.3 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Major Product Offerings
7.8.4 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global Market (2017-2022)
7.8.5 AzurRx Biopharma Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Opportunities & Trends in Global Market
Table 2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Drivers in Global Market
Table 3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Restraints in Global Market
Table 4. Key Players of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics in Global Market
Table 5. Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Type
Table 9. List of Global Tier 1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 32. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. Allergan Corporate Summary
Table 34. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 35. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. Nordmark Arzneimittel Corporate Summary
Table 37. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 38. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Digestive Care Corporate Summary
Table 40. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 41. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Janssen Pharmaceuticals Corporate Summary
Table 43. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 44. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. Cilian Corporate Summary
Table 46. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 47. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. Anthera Pharmaceuticals Corporate Summary
Table 49. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 50. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. AzurRx Biopharma Corporate Summary
Table 52. AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 53. AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Opportunities & Trends in Global Market
Table 2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Drivers in Global Market
Table 3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Restraints in Global Market
Table 4. Key Players of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics in Global Market
Table 5. Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Type
Table 9. List of Global Tier 1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 32. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. Allergan Corporate Summary
Table 34. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 35. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. Nordmark Arzneimittel Corporate Summary
Table 37. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 38. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Digestive Care Corporate Summary
Table 40. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 41. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Janssen Pharmaceuticals Corporate Summary
Table 43. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 44. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. Cilian Corporate Summary
Table 46. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 47. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. Anthera Pharmaceuticals Corporate Summary
Table 49. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 50. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. AzurRx Biopharma Corporate Summary
Table 52. AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offerings
Table 53. AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Segment by Type in 2021
Figure 2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Segment by Application in 2021
Figure 3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2021
Figure 8. By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Segment by Type in 2021
Figure 2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Segment by Application in 2021
Figure 3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2021
Figure 8. By Type - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
